<div id="readability-page-1"><article>Not for distribution to United States wire services or for dissemination in the United StatesOnco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) (&#34;Onco&#34; or the &#34;Company&#34;) announces that it intends to complete a non-brokered private placement (the &#34;Private Placement&#34;) of up to 2,272,727 units of the Company (the &#34;Units&#34;) at a price of $0.88 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit shall consist of one common share (each a &#34;Share&#34;) and one-half of one common share purchase warrant (each whole warrant, a &#34;Warrant&#34;), with each Warrant entitling the holder to purchase one Share at an exercise price of $1.10 for a period of thirty-six (36) months.The Company also intends to issue Shares equal to 1.0% of the total of Shares issued in the Private Placement (the &#34;Admin Fee Shares&#34;) to an arm's-length third party, as an administrative fee for their assistance with the Private Placement.In connection with the Private Placement, the Company may pay finders' fees and/or issue finders' warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Private Placement.Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives and for investor relations purposes.The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.About Onco-Innovations LimitedOnco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.ON BEHALF OF ONCO-INNOVATIONS LIMITED,&#34;Thomas O'Shaughnessy&#34; Chief Executive OfficerFor more information, please contact:Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 investors@oncoinnovations.comThe CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as &#34;will&#34;, &#34;may&#34;, &#34;potential&#34;, &#34;should&#34;, &#34;anticipate&#34;, &#34;expects&#34; and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.SOURCE: Onco-Innovations LimitedView the original press release on ACCESS Newswire<img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="0" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg"/></article></div>

Onco-Innovations Limited announces a non-brokered private placement of up to 2,272,727 units at $0.88 per unit, aiming for gross proceeds of $2 million. Each unit includes one common share and one-half warrant, with warrants exercisable at $1.10 for 36 months. The funds will support general corporate purposes and R&D. The placement is subject to regulatory approvals and securities will have a four-month hold period. The company specializes in cancer research and has exclusive rights to patented technology targeting solid tumors.

StockTitan

Onconetix

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Oncolytics Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Inovio Pharma

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Onco-Innovations Announces Private Placement | ONNVF Stock News